AMPH Amphastar Pharmaceuticals, Inc.
USHealthcareAs of 2026-07-10 16:00
Why AMPH matters now
Amphastar Pharmaceuticals, Inc. (AMPH) is a US stock in Healthcare. The latest InvestLog snapshot shows $18.72 with -1.58% on the session and $825.4M in market capitalization; recent performance reads 1-month +5.56% and YTD -29.76%.
The latest financial table shown here is Q1 2026, with revenue of $171.2M, net income of $6.4M, and EPS of $0.14. Investors can compare that operating picture with valuation signals such as P/E 9.54 and FCF yield 16.3%.
The latest indexable market news headline is "New Strong Sell Stocks for June 23rd" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Hold with a median target of $20.50; recent insider activity includes Lee Howard filing F-InKind. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
9.54
PEG
—
P/B
1.10
P/S
1.15
EV/EBITDA
7.02
DCF Value
$129.17
FCF Yield
16.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
47.3%
Operating Margin
16.2%
Net Margin
11.0%
ROE
10.2%
ROA
4.8%
ROIC
6.0%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $171.2M | $6.4M | $0.14 |
| Q4 2025 | $183.1M | $24.4M | $0.51 |
| FY 2025 | $719.9M | $98.1M | $2.03 |
| Q3 2025 | $191.8M | $17.4M | $0.37 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$20.50
Target (Median)
$20.50
Target Range
$19.00 - $22.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
US
Exchange
—
Beta
0.90
Amphastar Pharmaceuticals, Inc., established in 1996 and based in Rancho Cucamonga, California, functions as a biopharmaceutical enterprise. The company is engaged in the creation, production, commercialization, and distribution of both generic and proprietary pharmaceutical products, which include injectables, inhalants, and intranasal formulations. Its market presence extends across the United States, China, and France. Amphastar's operations are divided into two primary segments: Finished Pharmaceutical Products and Active Pharmaceutical Ingredients (API). The company's extensive product portfolio encompasses a variety of crucial medications. These feature Primatene Mist, an over-the-counter epinephrine inhaler for the temporary alleviation of mild asthma symptoms; Enoxaparin, a low molecular weight heparin utilized for the prevention and treatment of deep vein thrombosis; and Naloxone, an essential treatment for opioid overdose. Other significant offerings include emergency Glucagon injection kits; Cortrosyn, a diagnostic agent for adrenocortical insufficiency; and Amphadase, a bovine-sourced hyaluronidase injection that aids in the absorption and dispersion of other administered drugs. Amphastar additionally supplies Epinephrine injections for severe allergic reactions; various lidocaine products (such as a jelly for urological procedures and a topical solution for other applications); Phytonadione injection (Vitamin K1) for newborns; and specialized emergency syringe products for hospital use. Furthermore, the company provides Morphine injections for patient-controlled analgesia and Lorazepam injections for surgical and medical procedures. More advanced therapeutics consist of Neostigmine methylsulfate injection to manage myasthenia gravis and reverse muscle relaxant effects, and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Beyond its finished pharmaceutical goods, Amphastar also acts as a distributor for recombinant human insulin API and porcine insulin API. The company caters to a broad spectrum of healthcare providers, including hospitals, various care facilities, clinics, and physicians' offices.